|
|
|
|
| LEADER |
03669nam a2200853Ia 4500 |
| 001 |
10-1038-s41523-022-00386-1 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 23744677 (ISSN)
|
| 245 |
1 |
0 |
|a Immunotherapy for early triple negative breast cancer: research agenda for the next decade
|
| 260 |
|
0 |
|b Nature Research
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1038/s41523-022-00386-1
|
| 520 |
3 |
|
|a For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II–III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC. © 2022, The Author(s).
|
| 650 |
0 |
4 |
|a adjuvant therapy
|
| 650 |
0 |
4 |
|a anthracycline
|
| 650 |
0 |
4 |
|a antiapoptotic activity
|
| 650 |
0 |
4 |
|a antibody drug conjugate
|
| 650 |
0 |
4 |
|a atezolizumab
|
| 650 |
0 |
4 |
|a biological marker
|
| 650 |
0 |
4 |
|a breast cancer
|
| 650 |
0 |
4 |
|a cancer chemotherapy
|
| 650 |
0 |
4 |
|a cancer immunotherapy
|
| 650 |
0 |
4 |
|a cancer prognosis
|
| 650 |
0 |
4 |
|a capecitabine
|
| 650 |
0 |
4 |
|a carboplatin
|
| 650 |
0 |
4 |
|a circulating tumor DNA
|
| 650 |
0 |
4 |
|a colitis
|
| 650 |
0 |
4 |
|a cyclophosphamide
|
| 650 |
0 |
4 |
|a disease exacerbation
|
| 650 |
0 |
4 |
|a disease free survival
|
| 650 |
0 |
4 |
|a distant disease free survival
|
| 650 |
0 |
4 |
|a durvalumab
|
| 650 |
0 |
4 |
|a estrogen receptor
|
| 650 |
0 |
4 |
|a event free survival
|
| 650 |
0 |
4 |
|a financial distress
|
| 650 |
0 |
4 |
|a hepatitis
|
| 650 |
0 |
4 |
|a HLA system
|
| 650 |
0 |
4 |
|a hormone receptor positive breast cancer
|
| 650 |
0 |
4 |
|a hyperthyroidism
|
| 650 |
0 |
4 |
|a hypophysitis
|
| 650 |
0 |
4 |
|a hypothyroidism
|
| 650 |
0 |
4 |
|a immune checkpoint inhibitor
|
| 650 |
0 |
4 |
|a major histocompatibility antigen class 1
|
| 650 |
0 |
4 |
|a major histocompatibility antigen class 2
|
| 650 |
0 |
4 |
|a minimal residual disease
|
| 650 |
0 |
4 |
|a neoadjuvant chemotherapy
|
| 650 |
0 |
4 |
|a nonhuman
|
| 650 |
0 |
4 |
|a olaparib
|
| 650 |
0 |
4 |
|a overall survival
|
| 650 |
0 |
4 |
|a paclitaxel
|
| 650 |
0 |
4 |
|a pembrolizumab
|
| 650 |
0 |
4 |
|a placebo
|
| 650 |
0 |
4 |
|a pneumonia
|
| 650 |
0 |
4 |
|a programmed death 1 ligand 1
|
| 650 |
0 |
4 |
|a Review
|
| 650 |
0 |
4 |
|a sacituzumab govitecan
|
| 650 |
0 |
4 |
|a skin toxicity
|
| 650 |
0 |
4 |
|a survival analysis
|
| 650 |
0 |
4 |
|a taxane derivative
|
| 650 |
0 |
4 |
|a therapy escalation
|
| 650 |
0 |
4 |
|a triple negative breast cancer
|
| 650 |
0 |
4 |
|a tumor associated leukocyte
|
| 650 |
0 |
4 |
|a tumor mutational burden
|
| 650 |
0 |
4 |
|a veliparib
|
| 700 |
1 |
0 |
|a Andrè, F.
|e author
|
| 700 |
1 |
0 |
|a Bianchini, G.
|e author
|
| 700 |
1 |
0 |
|a Cortes, J.
|e author
|
| 700 |
1 |
0 |
|a Corti, C.
|e author
|
| 700 |
1 |
0 |
|a Curigliano, G.
|e author
|
| 700 |
1 |
0 |
|a Mittendorf, E.A.
|e author
|
| 700 |
1 |
0 |
|a Rugo, H.
|e author
|
| 700 |
1 |
0 |
|a Schmid, P.
|e author
|
| 700 |
1 |
0 |
|a Tarantino, P.
|e author
|
| 700 |
1 |
0 |
|a Tolaney, S.M.
|e author
|
| 773 |
|
|
|t npj Breast Cancer
|
